Akebia Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported revenue was USD 56.38 million compared to USD 126.37 million a year ago. Net loss was USD 11.17 million compared to net income of USD 29.45 million a year ago.

Basic loss per share from continuing operations was USD 0.06 compared to basic earnings per share from continuing operations of USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to diluted earnings per share from continuing operations of USD 0.15 a year ago.